Lantheus Holdings, Inc. (NASDAQ:LNTH) Expected to Post Quarterly Sales of $165.10 Million
Analysts expect Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) to report revenue of $165.10 million for the current quarter, according to Zacks. Two analysts released earnings estimates for Lantheus, with the lowest sales estimate of $164.50 million and the highest estimate of $165.70 million. Lantheus recorded sales of $92.51 million in the same quarter last year, which would indicate a positive growth rate of 78.5% year over year. The company is due to announce its next earnings report on Tuesday, May 3.
On average, analysts expect Lantheus to record annual sales of $704.30 million for the current year, with estimates ranging from $700.90 million to $707.70 million. For the next fiscal year, analysts expect the company to post sales of $791.90 million, with estimates ranging from $788.20 million to $795.60 million. Zacks Investment Research sales averages are an average average based on a survey of research analysts who cover Lantheus.
Lantheus (NASDAQ:LNTH – Get Rating) last released its results on Thursday, February 24. The medical equipment supplier reported earnings per share (EPS) of $0.25 for the quarter, beating the Zacks consensus estimate of $0.17 by $0.08. The company posted revenue of $129.60 million for the quarter, versus analyst estimates of $111.77 million. Lantheus posted a positive return on equity of 6.80% and a negative net margin of 16.76%. The company’s revenue for the quarter increased 37.7% compared to the same quarter last year. In the same quarter a year earlier, the company posted earnings per share of $0.07.
Several brokerages have published reports on LNTH. Zacks Investment Research upgraded Lantheus from a “sell” rating to a “buy” rating and set a price target of $32.00 for the company in a Thursday, February 24 report. SVB Leerink raised its price target on Lantheus shares from $34.00 to $75.00 and gave the stock an “outperform” rating in a Thursday, February 24 research report.
Lantheus stock opened Wednesday at $49.15. The company has a market capitalization of $3.33 billion, a P/E ratio of -46.81, a P/E/G ratio of 1.41 and a beta of 1.35. Lantheus has a 1-year low of $17.91 and a 1-year high of $50.00. The company has a 50-day simple moving average of $29.02 and a 200-day simple moving average of $27.13. The company has a debt ratio of 0.35, a quick ratio of 2.18 and a current ratio of 2.61.
Separately, CAO Andrea Sabens sold 1,242 Lantheus shares in a trade dated Tuesday, January 18. The shares were sold at an average price of $26.93, for a total value of $33,447.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Insiders of the company own 1.40% of the shares of the company.
Hedge funds and other institutional investors have recently been buying and selling shares of the company. Point72 Hong Kong Ltd bought a new equity stake in Lantheus in Q3 worth $43,000. Cubist Systematic Strategies LLC bought a new position in Lantheus in Q2 worth approximately $69,000. Macquarie Group Ltd. increased its Lantheus equity stake by 218.5% in Q3. Macquarie Group Ltd. now owns 2,838 shares of the medical equipment supplier valued at $73,000 after acquiring 1,947 additional shares last quarter. First Manhattan Co. increased its equity stake in Lantheus by 39.5% during the third quarter. First Manhattan Co. now owns 4,324 shares of the medical equipment supplier valued at $111,000 after buying 1,224 additional shares last quarter. Finally, O Shaughnessy Asset Management LLC increased its stake in Lantheus by 20.7% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 5,056 shares of the medical equipment supplier worth $130,000 after purchasing an additional 866 shares during the period. Institutional investors hold 95.27% of the company’s shares.
About Lantheus (Get a rating)
Lantheus Holdings, Inc provides diagnostic imaging and nuclear medicine products. The company develops products that aid healthcare professionals in patient management and outcomes and assist clinicians in the detection of cardiovascular disease. It operates through the US and International geographic segments.
Get a Free Copy of Zacks’ Research Report on Lantheus (LNTH)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Lantheus right now?
Before you consider Lantheus, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes big…and Lantheus wasn’t on the list.
Although Lantheus currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here